» Articles » PMID: 15882197

Interference of Lactobacillus Plantarum with Pseudomonas Aeruginosa in Vitro and in Infected Burns: the Potential Use of Probiotics in Wound Treatment

Overview
Publisher Elsevier
Date 2005 May 11
PMID 15882197
Citations 103
Authors
Affiliations
Soon will be listed here.
Abstract

This study evaluated the ability of the probiotic organism Lactobacillus plantarum to inhibit the pathogenic activity of Pseudomonas aeruginosa, both in vitro and in vivo, and investigated the mechanisms involved in such protection. L. plantarum whole cultures, culture filtrates (acid filtrate and neutralised acid filtrate) and isolated, washed cells were tested in vitro for their effects on the production of the P. aeruginosa quorum-sensing signal molecules, acyl-homoserine-lactones (AHLs), and two virulence factors controlled by these signal molecules, elastase and biofilm. All were inhibited by L. plantarum cultures and filtrates, but not by isolated, washed cells. The acid L. plantarum growth medium itself had some inhibitory activity, but the greatest activity was exerted by the whole culture. To test the in-vivo activity of L. plantarum, a burned-mouse model was used in which burns infected with P. aeruginosa were treated with L. plantarum at 3, 4, 5, 7 and 9 days post-infection. Samples from skin, liver and spleen taken after 5, 10 and 15 days demonstrated inhibition of P. aeruginosa colonisation by L. plantarum. There was also an improvement in tissue repair, enhanced phagocytosis of P. aeruginosa by tissue phagocytes, and a decrease in apoptosis at 10 days. These results indicate that L. plantarum and/or its by-products are potential therapeutic agents for the local treatment of P. aeruginosa burn infections.

Citing Articles

The Skin Microbiome: A New Key Player in Melanoma, From Onset to Metastatic Stage.

Lorphelin J, Dompmartin A, Dreno B Pigment Cell Melanoma Res. 2025; 38(2):e13224.

PMID: 40016867 PMC: 11868406. DOI: 10.1111/pcmr.13224.


Opportunities and challenges of bacterial extracellular vesicles in regenerative medicine.

Guo J, Huang Z, Wang Q, Wang M, Ming Y, Chen W J Nanobiotechnology. 2025; 23(1):4.

PMID: 39754127 PMC: 11697683. DOI: 10.1186/s12951-024-02935-1.


Advances in Microbiome-Based Therapeutics for Dermatological Disorders: Current Insights and Future Directions.

Madaan T, Doan K, Hartman A, Gherardini D, Ventrola A, Zhang Y Exp Dermatol. 2024; 33(12):e70019.

PMID: 39641544 PMC: 11663288. DOI: 10.1111/exd.70019.


UBLP-40 Versus the Combined Formula of UBLP-58 and UBBL-64 in Excisional Wound Healing: A Cellular Perspective.

Moysidis M, Chorti A, Cheva A, Abba Deka I, Tzikos G, Kosmidis C Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598326 PMC: 11597307. DOI: 10.3390/ph17111414.


Modulations of the skin microbiome in skin disorders: A narrative review from a wound care perspective.

Piazzesi A, Scanu M, Ciprandi G, Putignani L Int Wound J. 2024; 21(10):e70087.

PMID: 39379177 PMC: 11461044. DOI: 10.1111/iwj.70087.